Vitrolife AB (publ)

OM:VITR Stock Report

Market Cap: SEK 29.2b

Vitrolife Past Earnings Performance

Past criteria checks 0/6

Vitrolife's earnings have been declining at an average annual rate of -71.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 24.9% per year.

Key information

-71.9%

Earnings growth rate

-71.3%

EPS growth rate

Biotechs Industry Growth0.7%
Revenue growth rate24.9%
Return on equity-29.0%
Net Margin-107.0%
Next Earnings Update30 Jan 2025

Recent past performance updates

Recent updates

Is Vitrolife (STO:VITR) A Risky Investment?

Nov 27
Is Vitrolife (STO:VITR) A Risky Investment?

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Aug 21
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Jul 20
Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth

Jul 18
Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth

Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

Apr 03
Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Mar 07
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Feb 05
Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Jan 05
Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Dec 15
Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Nov 06
Is Vitrolife (STO:VITR) A Risky Investment?

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Aug 25
An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Vitrolife (STO:VITR) Could Easily Take On More Debt

Aug 03
Vitrolife (STO:VITR) Could Easily Take On More Debt

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

May 26
Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

Is Vitrolife (STO:VITR) A Risky Investment?

Jan 23
Is Vitrolife (STO:VITR) A Risky Investment?

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Oct 18
Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Sep 09
Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Jul 07
Is Vitrolife (STO:VITR) A Risky Investment?

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

May 26
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Mar 31
Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Feb 07
Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Revenue & Expenses Breakdown

How Vitrolife makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OM:VITR Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,555-3,8051,181117
30 Jun 243,535-3,7991,150118
31 Mar 243,499-3,8361,118126
31 Dec 233,512-3,8511,117127
30 Sep 233,4624021,092122
30 Jun 233,4123881,076124
31 Mar 233,3364121,048133
31 Dec 223,2343941,002143
30 Sep 222,893353961157
30 Jun 222,501349811151
31 Mar 222,054305656133
31 Dec 211,681341503114
30 Sep 211,549415353103
30 Jun 211,46439933394
31 Mar 211,29132530891
31 Dec 201,24628731192
30 Sep 201,27327632497
30 Jun 201,331294342102
31 Mar 201,502377365105
31 Dec 191,480383351100
30 Sep 191,39137134288
30 Jun 191,29733931880
31 Mar 191,19932429374
31 Dec 181,15131028472
30 Sep 181,10229427870
30 Jun 181,06428427670
31 Mar 181,06627627669
31 Dec 171,04626427069
30 Sep 171,02625526671
30 Jun 1799123426270
31 Mar 1791321125468
31 Dec 1685619025062
30 Sep 1680418823555
30 Jun 1677119623155
31 Mar 1674718622353
31 Dec 1572218322056
30 Sep 1566015421356
30 Jun 1560913719548
31 Mar 1555412218645
31 Dec 1451110917242
30 Sep 144979616852
30 Jun 144817716658
31 Mar 144676716559
31 Dec 134535616459

Quality Earnings: VITR is currently unprofitable.

Growing Profit Margin: VITR is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VITR is unprofitable, and losses have increased over the past 5 years at a rate of 71.9% per year.

Accelerating Growth: Unable to compare VITR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VITR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).

Return on Equity

High ROE: VITR has a negative Return on Equity (-28.96%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 10:15
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vitrolife AB (publ) is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik CasselABG Sundal Collier Sponsored
null nullABG Sundal Collier Sponsored
Kallum TitchmarshBofA Global Research